Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

- Adenocarcinoma Neversmoking
  - LUN0112 Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
    - PI: Wakelee
    - Sponsor: NCTN

- EGFR Exon 20 Insertions
  - LUN0113 Phase III TAK-788 First-Line Tx vs Platinum-Based Chemo in NSCLC w/ EGFR Exon 20 Insertion Mutations
    - PI: Neal
    - Sponsor: Takeda

- EGFR Mutant (Not Exon 20)
  - LUN0128 Phase II Open-Label Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Advanced or Metastatic Solid Tumors including EGFR-Mutated Non-Small Cell Lung Cancer
    - PI: Neal
    - Sponsor: Janssen Research & Development, LLC

- Without Actionable Genomic Alterations
  - ECOG-ACRIN- EA5182 Randomized Phase III Study of Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment in Metastatic EGFR-Mutant NSCLC
    - PI: Neal
    - Sponsor: ECOG-ACRIN

- LUN0125 Phase II Sunitinib Osimertinib Combinations in First-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer Without Actionable Genomic Alterations
    - PI: Neal
    - Sponsor: Gilead Sciences, Inc.

**KEY**

- **灰**: Pending
- **蓝**: Open for Enrollment
- **Link**: Optional Path
- **黄**: Trial Posting
- **黑**: Extension Study
- **白**: Immunotherapy
- **橙**: Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu